Metabolic Program(s)

About Mercury Bio

Mercury Bio is a private, pre-clinical stage biotech company pioneering a novel approach to treating diseases driven by intracellular pathology. The company's proprietary MB-TIP™ platform combines engineered nanobodies (yEV™) and AI-informed design to deliver proteins, nanobodies, RNA, and small molecules across biological barriers and into cells, a significant challenge for existing biologics. With an initial focus on high-unmet-need neurodegenerative diseases, Mercury Bio aims to move beyond symptom management to potentially alter disease progression by targeting pathogenic proteins inside neurons. The company is advancing a pipeline across neurology, oncology, regenerative medicine, metabolic, and viral diseases, with pre-clinical validation from research partners like Vanderbilt University.

Therapeutic Areas

Other Not Specified Drugs